Equities research analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to post earnings per share of ($0.06) for the current quarter, according to Zacks. Two analysts have made estimates for Alimera Sciences’ earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.05). Alimera Sciences reported earnings per share of ($0.04) in the same quarter last year, which indicates a negative year over year growth rate of 50%. The company is expected to issue its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Alimera Sciences will report full year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.29) to ($0.25). For the next financial year, analysts anticipate that the business will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.17) to ($0.11). Zacks’ EPS averages are an average based on a survey of research analysts that cover Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $10.92 million for the quarter, compared to analyst estimates of $10.78 million.

Several research firms have issued reports on ALIM. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Thursday, August 2nd. HC Wainwright set a $3.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a research report on Thursday, September 6th. Cowen reissued a “buy” rating and issued a $3.00 target price on shares of Alimera Sciences in a research report on Wednesday, September 5th. Finally, B. Riley began coverage on shares of Alimera Sciences in a research report on Friday, June 29th. They issued a “buy” rating and a $2.75 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $2.44.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALIM. BlackRock Inc. boosted its position in shares of Alimera Sciences by 28.5% in the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 60,327 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Alimera Sciences by 20.8% in the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 99,000 shares during the last quarter. Finally, Stonepine Capital Management LLC boosted its position in shares of Alimera Sciences by 13.0% in the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock worth $6,830,000 after acquiring an additional 801,151 shares during the last quarter. 51.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alimera Sciences stock traded up $0.01 during mid-day trading on Monday, hitting $0.96. 36,920 shares of the stock were exchanged, compared to its average volume of 152,029. Alimera Sciences has a twelve month low of $0.74 and a twelve month high of $1.46. The stock has a market capitalization of $68.64 million, a P/E ratio of -3.32 and a beta of 1.51. The company has a debt-to-equity ratio of -0.60, a current ratio of 3.85 and a quick ratio of 3.61.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Further Reading: What is the NASDAQ?

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.